What Has Been The Evolution of the Oral Proteins And Peptides Market in Recent Years?
The oral proteins and peptides market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for oral proteins and peptides has seen gigantic growth. The market is anticipated to expand from a size of $1.27 billion in 2024 to $1.56 billion in 2025, with a compound annual growth rate (CAGR) of 22.7%.
This significant growth during the historical period can be credited to various factors like the increment in chronic disease cases, heightened investment in biotechnology for creating oral protein-focused treatments, a growing preference among consumers for non-invasive treatments, the expansion of the biopharmaceutical industry, and an increased emphasis on personalized medicine.
What Is the Forecasted Market Size and Growth Rate for The Oral Proteins And Peptides Market Size In The Coming Years?
The oral proteins and peptides market is expected to maintain its strong growth trajectory in upcoming years.
• The market for oral proteins and peptides is predicted to exponentially inflate over the coming years, with a projected valuation of $3.49 billion in 2029, showcasing a compound annual growth rate (CAGR) of 22.3%.
This forthcoming expansion can be attributed to an amplified focus on patient-centered medicines, the escalating prevalence of aged individuals, increased healthcare spending, the emerging necessity for cancer diagnostics, and a rising preference for orally administered drugs. Notable emerging trends for the forecast period include the creation of innovative oral peptides with improved stability and efficacy, the usage of artificial intelligence in drug discovery for oral formulations, progress in medical treatments, enhancements in drug delivery technologies, and ground-breaking oral insulin formulations.
What Factors Are Driving Growth In The Oral Proteins And Peptides Market?
The expansion of the biopharmaceutical sector is anticipated to stoke the progress of the oral proteins and peptides market. This sector, part of the larger pharmaceutical industry, primarily centers its attention on the innovation, production, and marketization of drugs springing from biological origins. Factors contributing to this industry's ascension include advancements in biotechnology, a rising call for personalized medication, increased incidence of chronic ailments, and escalated investment in research and development. Leveraging oral proteins and peptides in biopharmaceuticals could give rise to the non-invasive delivery of therapeutic substances, heightening patient adherence and minimizing the necessity for injections. These molecules can specifically act upon certain diseases, potentially offering better stability and absorption in the digestive tract. Notably, as per data from the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade association based in Belgium representing the pharmaceutical sector, Europe's bio-pharmaceutical output summed up to $384,200 million (€340,000 million) in 2022, marking a roughly 4.95% growth from $366,267 million (€323,950 million) in 2021. Thus, the progression of the biopharmaceutical arena propels the upward trend of the oral proteins and peptides market.
What Are The Main Segments Of The Global Oral Proteins And Peptides Market?
The oral proteins and peptidesmarket covered in this report is segmented –
1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer
Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors
Pre-Book The Oral Proteins And Peptides Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Oral Proteins And Peptides Market?
Leading enterprises in the oral proteins and peptides market are directing their efforts towards the creation of novel products such as Oral Semaglutide to improve patient compliance and comfort. Oral semaglutide is a significant breakthrough and represents considerable progress in the realm of oral proteins and peptides. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has traditionally been injected to treat type 2 diabetes, and more recently, obesity. For example, in January 2022, healthcare firm Novo Nordisk India, headquartered in India, introduced the world's inaugural oral semaglutide, heralding a transformative progress in diabetes management. Semaglutide, which is a GLP-1 receptor analogue (GLP-1 RA) and previously only available in an injectable form, is now available as a more user-friendly oral alternative for managing type 2 diabetes. This innovation is not simply a revolution in diabetes treatment, it also paves the way for future advancements in oral insulin formulations, potentially offering more effective and patient-centered treatment alternatives.
Who Are the Key Players In The Oral Proteins And Peptides Market?
Major companies operating in the oral proteins and peptides market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi S.A.
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Ipsen S.A.
• Biocon Limited
• Xeris Pharmaceuticals Inc.
• Adocia S.A.
• Zealand Pharma A/S
• Diabetology Ltd.
• Oramed Pharmaceuticals Inc.
• Palatin Technologies Inc.
• Entera Bio Ltd.
What Is The Most Dominant Region In The Oral Proteins And Peptides Market?
North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
